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Abstract: Introduction: Optimizing erectile dysfunction (ED) remains a clinically significant endeavor
as insufficient outcomes from oral, injectable and even surgical approaches to treatment remain less
than ideal. In this report, we integrate evolving knowledge and provide an algorithmic approach for
the clinician to fine-tune management. Methods: We performed a PubMed and Medline search of
Erectile Dysfunction treatment optimization, enhanced patient efficacy for ED, and why men fail ED
treatment. All relevant papers for the past two decades were reviewed. Results: Establishing the
goals and objectives of the patient and partner while providing detailed instructions for treatment
can minimize failures and create an environment that allows treatment optimization. A thorough
work-up may identify reversible or contributing causes. We identified several areas where treatment
of ED could be optimized. These include; management of associated medical conditions, lifestyle
improvements, PDE5 inhibitor prescription strategies, management of hypogonadism and the
initiation of intracavernosal injection therapy (ICI). Conclusions: In our view, once a man presents for
help to the clinician, use of the simple strategies identified in this review to optimize the tolerability,
safety and effectiveness of the selected treatment should result in enhanced patient and partner
satisfaction, with improved outcomes.
Keywords: erectile dysfunction; treatment optimization; PDE-5 inhibitors; testosterone
1. Introduction
The modern era of erectile dysfunction (ED) treatment was ushered into the mainstream
consciousness of physicians with the Massachusetts Male Aging Study (MMAS), published in 1994 [1].
It demonstrated that evaluation of ED was possible, that more than 50% of men between 40 and 70 years
of age, had some level of sexual dysfunction and identified key risk factors. The past two decades have
been witness to dramatic advances in both diagnostic and therapeutic approaches in management
of men and their partners suffering from ED. Use of duplex ultrasound imaging which enables the
treating physician to evaluate cavernous arterial blood flow, smooth muscle content of the penis and
visualize structural abnormalities within the penis, coupled with a greater understanding of the role
and importance of testosterone, are just two examples of these developments [2]. Arguably more
impactful than these advances has been the cultural change in comfort level among many societies to
talk about ED and the agreement by many to seek help. These changes now make it acceptable for
many patients to ask for help and have trained clinicians able to evaluate and offer a wide range of
therapies, some reversing the underlying pathology, while others provide enhanced penile function.
While there existed effective therapeutic agents prior to the approval of sildenafil in 1998, they were
highly invasive and fraught with significant adverse events that limited their widespread acceptance.
Intracavernous vasoactive agents, initially popularized in the 1980s and 1990s, required intra-penile
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injections, exposed the user to the risk of priapism and corporal fibrosis, and could only be offered
by specialty centers. Following the approval of sildenafil citrate (Viagra) in 1998, the field has been
transformed into one in which the vast majority of caregivers and prescribers are now non-experts.
The expansion of the number of prescribers has led to many more patients being treated, but, given the
lack of expertise among some treating physicians, has resulted in treatment failures.
Despite the great strides which have been achieved in the field, clinicians are still faced with
men who are prescribed ED therapy but either do not return or are disappointed as a consequence
of the medical therapy being deemed ineffective. It is the goal of this review to define the optimal
strategy that can be used to refine the diagnosis and fine-tune the selection of therapy to provide
the user and their partner with the ideal set of instructions and information for use, that result in an
effective outcome.
Previous reports have identified a number of key elements of diagnosis and treatment that can
increase success rates: [3]
1. Understanding that not all attempts will be positive—realistic expectations of effectiveness.
2. Men with ED often have underlying medical issues and optimization of these can
improve outcome.
3. Reinforcing timing and dosing information for oral agents.
4. Choice of agent needs to meet patient and partner goals.
2. Methods
We performed PubMed and Medline searches of ED treatment optimization, enhanced patient
efficacy for ED and why men fail ED treatment, reviewing all relevant English language papers for the
past two decades.
3. Results
3.1. Diagnosis and Assessment Options
Critical to the diagnosis and management of ED is patient engagement and a supportive
physician/patient relationship [4]. Patient goals and expectations are at the forefront of the discussion
and should incorporate the partner when possible [5,6]. Although patients will often present
with specific symptoms, emphasis should be placed on evaluating and addressing any underlying
conditions [5,7,8].
The ED assessment begins with a comprehensive history and a physical exam. The history should
focus on medical, sexual and psychosocial contributors to ED with specific attention to risk factors
including cigarette smoking, diabetes, hypertension and cardiovascular health status and a history of
pelvic surgery [5,8]. Validated questionnaires such as the International Index for Erectile Function
(IIEF), the Sexual Health Inventory for Men (SHIM) and the Erection Hardness Score (EHS) are useful
in both assessing ED and monitoring for response to treatment [6,9,10]. Clinicians should aim to
ascertain the patient’s concerns, impact of their symptoms and goals of treatment [7].
A focused physical exam should be conducted aiming to identify any genital abnormalities (i.e.,
penile plaques) that may be contributing to ED or signs of systemic comorbidities such as endocrine,
sensory loss or evident vascular insufficiency [5].
Consensus guidelines recommend laboratory testing assessing for common etiologies of ED
including diabetes, dyslipidemia and atherosclerosis [5,8]. Hormone testing is an option for further
assessment, though its role remains controversial. Most societies agree it has a role in men who have
failed PDE-5 inhibitors, exhibit hypoactive desire, and in all men with both ED and diabetes due to the
high concomitance of hypogonadism, ED, and diabetes [5,11]. Further testing including assessment of
thyroid function and a comprehensive hormone panel may be indicated in select patients [5,9].
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Specialized testing such as a psychological assessment, nocturnal penile tumescence, vascular
assessment, and penile duplex ultrasound (DUS) may aid in further clarifying the etiology of ED;
however, it is often reserved for select cases. DUS is often combined with intracavernosal injection (ICI)
of vasoactive substances allowing for the demonstration of penile plaques, curvature and vascular
response. In men who have failed PDE-5 inhibitors, it may serve as a useful adjunct for diagnosing ED
of vasculogenic etiology [8].
3.2. Associated Conditions
Multiple comorbidities have well-established connections to ED including diabetes
mellitus, hypertension, dyslipidemia, metabolic syndrome, depression, and lower-urinary-tract
symptoms [5,7,8,12–14]. Given the association between ED and cardiovascular, coronary artery,
and cerebrovascular disease, many societies recommend further evaluation of men presenting with
arteriogenic ED as it may be a harbinger for preexisting or subclinical disease [5,8,15]. Modifying these
risk factors through lifestyle changes and pharmacotherapy may improve, prevent or, in some cases,
reverse ED entirely and lead to improved overall health.
Patients with cardiac conditions that pose a significant health risk should be assessed by a
cardiologist prior to commencing PDE-5 inhibitor use. Visual conditions that also necessitate caution
when considering PDE-5 inhibitor use are non-arteritic anterior ischemic optic neuropathy and a
crowded optic disc [5,7,8].
Gupta et al. (2011) performed a meta-analysis to assess the effect of both lifestyle interventions
and pharmacotherapy (atorvastatin) on erectile function [16]. The results showed an IIEF score
improvement of 2.7 points. Further analysis separating lifestyle and pharmacotherapy identified an
IIEF score improvement of 2.4 and 3.1, respectively. While the clinical significance is questionable,
given PDE-5 inhibitor IIEF improvements of up to 7–10 points, it is important to note that three of the
six trials and 35% of the total patients involved had concurrent PDE-5 inhibitor use. Thus, CVD risk
factor reduction through lifestyle and pharmacotherapy may provide additive benefit with PDE-5
inhibitor use for erectile function.
Esposito et al. (2004) identified a relationship between physical activity and erectile function [14].
A total of 110 obese men with ED and minimal comorbidity were randomized to a weight-loss/increased
physical activity program vs. receipt of general health information (control). The groups were followed
for two years. Improvements were seen in body mass index (BMI) and IIEF score conferring a
four-point increase compared to the control arm. In another trial by Esposito et al. (2006), 65 men
with metabolic syndrome were randomized to a Mediterranean diet vs. a standard diet [17]. ED
was not a specific inclusion criterion. Following two years, improvements in endothelial function
and inflammatory markers were noted in the Mediterranean diet group. This was associated with a
3.7 IIEF score improvement in the Mediterranean diet group. Although these studies used small sample
sizes with limited generalizability, they provided evidence as to the effect of lifestyle interventions on
erectile function.
3.3. Psychological Disorders
The three major psychological aspects that are most relevant to sexual function are: (1) depressive
illness, (2) performance anxiety, and (3) couple dysfunction. These can be explored within a few
minutes during consultation, if indications of significant distress are found, the patient can be referred
appropriately [5,7,8,18].
Depression is an independent risk factor for ED. Furthermore, certain antidepressants may
exacerbate or lead to ED. PDE-5 inhibitor therapy in patients suffering from depression can enhance
erectile function even with concurrent antidepressant medication use, for example, selective-serotonin
reuptake inhibitors (SSRIs) [19].
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3.4. Medical Management and Optimization Strategies
PDE-5 inhibitors promote the erectile response by blocking the degradation of cyclic guanosine
monophosphate (cGMP). This promotes dilation of the corpus cavernosal smooth muscle and augments
erection following sexual stimulation [20].
Commercially available PDE-5 inhibitors include sildenafil, vardenafil, tadalafil, and avanafil.
Although no specific RCTs have been conducted comparing each of these agents, meta-analysis indicates
no significant differences in the efficacy of PDE-5 inhibitors relative to each other. Adverse events,
such as dyspepsia, headaches, nasal congestion, back pain, and visual disturbances, are comparable
with subtle differences [3–5,8,19–22].
In patients with ED, sildenafil was noted to improve erections in up to 70% [22]. The efficacy of
this treatment combined with its favourable adverse event profile have made it a first-line medical
therapy for ED. Sildenafil can be prescribed at a standard dose of 50 mg and titrated according to
response and side effects. Maximum plasma concentration is reached at 60 min post-consumption, and
the therapeutic effect lasts for 12 h, making it best suited to those individuals whose sexual encounters
occur at a predictable time [23,24]. However, in our opinion, a starting dose of 100 mg has better
efficacy and a tolerable side effect profile and reduces the risk of nonresponse. It is our opinion that
this should be the starting dose.
Tadalafil is an alternative for those patients who may benefit from prolonged plasma drug
concentration over a 36 h period. It is useful in patients who desire that sexual activity occurs more
spontaneously [25,26]. It is effective within 30 min of administration. It is available in dosing increments
spanning 2.5–20 mg. In our opinion, a 20 mg starting dose has a similar side effect profile but has
greater efficacy across broad populations and, as such, we recommend that it be the starting dose.
Vardenafil, like tadalafil, achieves effective concentration 30 min after administration. Unlike
sildenafil, its effect is diminished by fatty meals [27,28]. Patients are typically started on a 10 mg
starting dose. Our recommendation is that a 20 mg dose be the optimal starting dosage for reasons of
efficacy and tolerability.
Avanafil, the most recent PDE5i to gain approval in North America, is highly efficacious at
inhibiting the PDE-5 enzyme. This makes optimizing treatment with regards to a diminished side
effect profile less challenging. Patients are regularly advised to take a starting dose of 100 mg 15 to
30 min prior to being sexually active. Patients are advised to take the drug once per day and to avoid
taking the drug with food for maximum effect [29,30].
Pharmacokinetic differences between the agents may provide physicians with the opportunity to
individualize treatment. For instance, the longer half-life of tadalafil can potentiate erectile responses
up to 36 h and its low-dose formulations allow for daily usage [31]. A shorter half-life, however,
may provide more rapid reversibility of the agent and minimize adverse events [21,22,29,32].
3.5. Contraindications and Drug–Drug Interactions with PDE-5Is
Caution should be used when PDE-5i are co-administered with certain medications, such as
nitrates or guanylate cyclase stimulators (these are typically contraindicated). Hypotension may also
occur with concurrent use of alpha-blockers and certain antiretroviral drugs. In this latter scenario,
we suggest thorough patient counselling, dose titration and temporal separation of the intake of the
different medications by several hours [5,7,8].
3.6. Management of Erectile Dysfunction in Patients with Spinal Cord Lesions
A systematic review and meta-analysis evaluating PDE-5 inhibitor use noted a marked
improvement of erectile function in patients with spinal cord injuries. The level of spinal cord
injury appears to be a predictor of PDE-5 inhibitor success, wherein lower motor neuron lesions may
have decreased efficacy [33,34]. Motivated men who respond inadequately to PDE-5 inhibitors may
benefit from specialist referral for further management.
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3.7. Prostate Cancer
ED in men with prostate cancer is often multifactorial and is a common side effect amongst all
treatment modalities [35].
Post-prostatectomy, men may experience ED due to nerve injury despite nerve-sparing
surgical approaches. This can contribute to the apoptosis of cavernosal smooth muscle and
contribute to persistent post-operative ED [36]. Erectile function recovery can take up to four
years post-operatively [8]. In vitro and in vivo data suggests PDE-5 inhibitor therapy may improve
post-operative tissue oxygenation and thereby inhibit hypoxia-associated fibrosis of the cavernosal
smooth muscle [36]. In a small trial, early use of sildenafil versus a placebo was seen to preserve
smooth muscle content [37]. Further studies have demonstrated that post prostatectomy patients
taking sildenafil nightly experience earlier return of spontaneous erections [6]. Favourable prognostic
factors for response to PDE-5 inhibitor therapy include preoperative erectile function, age <65 years,
and degree of neurovascular bundle preservation [38]. Penile rehabilitation strategies intended to
enhance erectile function recovery using various PDE-5 inhibitors (tadalafil, sildenafil, and vardenafil)
have been examined in a randomized placebo-controlled fashion. All three PDE-5 inhibitors improved
erectile function with use [39–41]. Only one study (Padma-Nathan et al., 2008) noted nightly sildenafil
for nine months followed by a drug-free washout period led to a statistically significant return of
spontaneous erections [39]. In contrary, a study by Pavlovich et al. in 2013, noted no difference in
recovery of erectile function, as measured by nocturnal penile tumescence and IIEF scores, when
comparing nightly sildenafil versus on-demand dosing [42]. Shortcomings of the data are length of
follow-up (up to 13 months), large dropout rates, and heterogeneity in operative technique and surgical
outcomes. The role of PDE-5 inhibitors in penile rehabilitation remains to be established [43].
Incidence of ED amongst patients undergoing external-beam radiotherapy generally ranges from
30–40% and this effect is initially delayed—occurring after the first year. Brachytherapy may help limit
the detrimental effects from radiation through targeted mapping and seed implantation. Regardless
of modality, radiotherapy-induced ED appears to be arteriogenic with no clear relationship between
radiation dose and the subsequent development of ED. PDE-5 inhibitors remain first-line agents for
medical therapy. Similarly, for post-prostatectomy men, there may be a role for early initiation of
penile rehabilitation initiatives post radiotherapy [44].
Androgen deprivation therapy (ADT) is critical in the management of metastatic prostate cancer
and can be used in a neoadjuvant or adjuvant setting. Androgen depletion causes a multitude of
changes leading to reduced sexual desire. This includes, and is not limited to, reduction in response
to endogenous vasodilators, altering compliance of corpus cavernosum and resulting in dysfunction
of the veno-occlusive mechanism important in erectile function [45]. Intermittent ADT, as opposed
to continuous ADT, may be used in the right clinical setting and this may help alleviate sexual
dysfunction [46]. The treatment algorithm for such patients remains similar with conservative and
medical treatment options trialed initially; however, early specialist referral may be warranted.
3.8. Treatment Failure
Although PDE-5 inhibitors have transformed the treatment paradigm for ED, they are not suitable
for all patients and not efficacious for others. When addressing men who have failed a trial of PDE-5
inhibitors, ensuring a proper dosing technique is essential. In a sildenafil treatment trial amongst
253 non-responders, 40% of patients were able to achieve a long-term satisfactory response through
in-office education and evaluation. The mean office time was 12 min, suggesting a short visit can
improve efficacy prior to declaring true treatment failure [47]. Additional strategies for suboptimal
responders include dose escalation or employing a low-dose daily dosing strategy [7]. Switching
between different types of PDE-5 inhibitors does not appear to improve response rates [7].
Hypertension, dyslipidemia, tobacco use, and poor glycemic control have been identified as
independent predictors of poor responses to sildenafil [19]. In patients deemed unresponsive to
sildenafil, two placebo-controlled trials showed treatment of hypertension and dyslipidemia with an
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angiotensin-converting enzyme and a statin, respectively, improved erectile function [3,4,6]. Studies
examining poor glycemic control have shown that increased hemoglobin A1c levels were correlated
with an increased incidence of ED over time [48]. However, it is not clear whether intensive glycemic
control in men with elevated hemoglobin A1c levels leads to improved erectile function. Although
not directly compared, the response rates as expected to PDE-5 inhibitor therapy are less in men with
diabetes compared to non-diabetic men. No particular oral agent appears to be superior. Oral PDE-5
inhibitors remain first-line in this patient cohort with no significant increase in adverse events [13,14,48].
3.9. Hypogondal Men and Testosterone Supplementation
Androgens act at the central nervous system, peripheral nervous system and in the penis to
preserve erectile function. At the penis, these actions include maintenance of trabecular smooth muscle,
regulation of precursor cell differentiation in the corpus cavernosum, maintenance of endothelial
function and maintenance of penile connective tissue including the tunica albuginea [49–51]. In animal
models, histologic changes coincident with ED can be induced by castration and then reversed by
testosterone therapy (TT) [52,53]. Limited data suggests similar histologic changes occur in humans
and may be related to ED [54,55].
Hypogonadism, compared to castration, may be a diagnostic challenge owing to variation in
testosterone levels and responsiveness to androgens in the population. Threshold levels at which
ED may present have been proposed by some authors, for example, 8.5 nmol/L for isolated ED
and 10.4 nmol/L for two of the following three symptoms: ED, decreased morning erections or low
libido [56,57]. These values align with the lower limit of normal of most testosterone assays and
the cut-off for hypogonadism in many clinical guidelines [58]. The suggestion is that men with low
testosterone and ED may benefit from replacement.
TT has been utilized as monotherapy for treatment of ED. One meta-analysis of 14 RCTs that
compared the effect of TT to placebo in men with ED demonstrated improved IIEF scores [59].
The greatest effect was observed when the analysis was restricted to those participants with a baseline
testosterone <8 nmol/L who demonstrated a mean increase in IIEF-EFD score of 2.95 points [59].
A similar increase of 2.64 points on the IIEF-EFD was seen in a recent, large RCT of hypogonadal men
with sexual symptoms treated with testosterone gel [60]. A more recent meta-analysis restricted to
four RCTs including hypogonadal men also demonstrated efficacy of TT in improving erectile function
in this population [61].
In hypogonadal men, androgens may improve the response to PDE5i in previous non-responders,
though the mechanisms of synergy are unclear [62]. One study of sildenafil non-responders with a
serum testosterone in the lower quartile of the normal range (10–13 nmol/L) demonstrated a 7.4-point
improvement in the IIEF-EFD after treatment with combined testosterone and sildenafil vs. sildenafil
alone [63]. In comparison, a meta-analysis of 12 trials evaluating the effect of TT added to PDE5i
therapy demonstrated no significant effect when the analysis was limited to the five placebo-controlled
trials [64]. A limitation in these trials has been a potential direct effect of PDE5i on serum testosterone
levels, negating the additive benefit of TT [65].
3.10. History of ICI
After first being introduced in 1982, ICI therapy has provided robust relief for men with neurogenic,
vasculogenic, psychogenic and mixed erectile dysfunction with success rates up to 95% in properly
identified populations [66–68]. Intracavernous cocktails can be delivered as mono-agents or as
combinations utilizing agents that address multiple molecular targets in the erectile pathway.
3.11. Alprostadil
Currently available as a monoagent and as a component of Trimix and Quadmix, Alprostadil
is a synthetic prostaglandin E1 analogue. Prostaglandin E1 exerts pro-erectile effects by increasing
intracellular cAMP by activating adenylate cyclase, resulting in smooth muscle relaxation [69].
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Alprostadil exhibits a dose response with dosages titrated up from 1.25 to 20 µg with patient
satisfaction rates approaching 80% [70]. It is currently the only FDA-approved injectable monoagent in
the treatment of ED. The most common adverse events are related to site of injection including pain
(11%) and hematoma (1.5%). As with other injection therapy, alprostadil carries the risk of priapism,
fibrosis and pain, though the rate of priapism is the lowest (0.36%) among available agents [71].
Our recommendation would be that a starting dose of 5 µg of PGE-1 and titration up to 20 µg would
salvage most non-responders and optimize therapy. If pain is a limiting factor, a switch to Bimix or
Papaverine montherapy can provide pain-free injection therapy. Care should be taken in neurogenic
patients where a robust response is expected given their normal underlying vasculature; therefore,
a smaller starting dose (2.5 µg) and a gentle titration may be appropriate.
3.12. Papaverine
Papaverine acts as a nonselective PDE-5 inhibitor preventing the degradation of cAMP and cGMP.
It has been shown to both increase the arterial flow and decrease venous outflow, with both mechanisms
working synergistically to increase tumescence [72]. Despite being the first intracavernosal agent,
described by Virag in 1982, it shows poor overall efficacy compared to other agents and a higher side
effect profile (most notably fibrosis) [66]. As a result, papaverine is seldomly used as monotherapy,
but is often present in formulations [73,74].
3.13. Phentolamine
Phentolamine acts as a nonselective alpha-adrenergic receptor antagonist that blocks sympathetic
(and thus anti-erectile) stimulation of the corporeal smooth muscle to improve tumescence. It shows
limited efficacy as a monoagent [75].
3.14. Combination Therapy
Papaverine/phentolamine (Bimix) utilizes the synergistic PDE-5 inhibition of papaverine and
alpha blockage of phentolamine, resulting in a response rate of 68.5% [73]. Overall, Bimix appears
to have improved success in achieving erections sufficient for penetration compared to papaverine
alone (54% vs. 50%); however, a higher incidence of penile fibrosis is observed [76]. The addition
of alprostadil to Bimix results in Trimix, and the addition of atropine results in Quadmix. Currently,
there is no commercially available formulation of Trimix, with multiple formulations discussed in the
literature making direct comparisons difficult. The only prospective trial to date had men progress
through four protocols from Bimix to Quadmix in increasing dosages. Of the 625 men involved, all but
15 achieved erections sufficient for penetration [77].
4. Conclusions
The ability to restore sexual functioning to the vast majority of men with ED is a present-day
reality, owing to advances in diagnosis and therapeutics. In truth, many men will never seek medical
care as they have decreased interest, an unwilling partner, or simply believe effective therapy does not
exist. In our view, once a man presents for help to the clinician, use of the simple step-wise strategies
identified in this review to optimize the tolerability, safety, and effectiveness of the selected treatment
should result in enhanced patient and partner satisfaction and improved outcomes (Figure 1).
Use of higher, rather than lower doses, multiple attempts, having the patient and partner
understand the time course of the drugs’ absorption, distribution and clearance, coupled with
clear detailed instructions for use often can avoid treatment failures and optimize erectile
dysfunction therapies.
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